Nimo

Study smarter with Nimo

Personalised revision that adapts to you. Ace your revision with unlimited practice questions that are designed to help you learn faster. We're slowly rolling out to more and more students.

Try Nimo

Evaluate monoclonal antibodies: advantages and risks

Infection and response • Monoclonal antibodies (biology only) (HT only)

Key concepts

What you'll likely be quizzed about

  • Monoclonal antibodies are identical antibodies produced from a single clone of cells that all recognize the same antigen.
  • Production begins by stimulating an animal’s immune system with a chosen antigen, followed by harvesting antibody-producing spleen cells and fusing them with immortal myeloma cells to create hybridoma cells.
  • These hybridomas can grow indefinitely and secrete large quantities of the specific antibody.
  • However, production has limiting factors including the time required for generating suitable hybridomas, the need for specialized laboratory facilities, and ethical concerns regarding the initial use of animal cells during the generation process.

Flashcards

Test your knowledge with interactive flashcards

What is a monoclonal antibody?

Click to reveal answer

An identical antibody produced from a single clone of cells that all bind the same specific antigen.

Key notes

Important points to keep in mind

Monoclonal antibodies are identical and specific to a single antigen, produced using hybridomas from spleen and myeloma cells.

High specificity provides significant advantages in diagnostics and targeted therapies by reducing off-target effects.

Targeted delivery allows concentration of toxic agents at disease cells, minimizing collateral damage compared to conventional chemotherapy.

Clinical trials can reveal unexpected side effects; safety monitoring is crucial for determining wider use.

Production complexities, costs, and ethical issues regarding initial animal use represent significant practical constraints.

Variability of antigens on disease cells can reduce effectiveness, necessitating combination therapies or alternative target identification.

Built with v0